HomeMCPWorkbenchSkills
HomeWorkbenchNotificationsMe
llms.txt · MCP GuidePrivacy Policy · Terms of Service · Supportv1.8.3
  1. Home
  2. /Compound

Clobetasol

HCID 5311051
New reaction
Print

Completing data — refresh the page later to see the latest

Basic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
Substructure searchFind similar structures

Basic information

CAS
25122-41-2
Standard SMILES
C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CCl
InChIKey
FCSHDIVRCWTZOX-DVTGEIKXSA-N
Molecular formula
C22H28ClFO4
Average molar mass
410.9 g/mol
Monoisotopic mass
410.1660152

Overview

Clobetasol is a 3-oxo-1,4-steroid that is 16beta-methylpregna-1,4-diene-3,20-dione bearing hydroxy groups at the 11beta and 17alpha positions, fluorine at position 9, and a chlorine substituent at position 21. It is used as its 17alpha-propionate ester to treat various skin disorders, including exzema and psoriasis. It has a role as a SMO receptor agonist and an anti-inflammatory drug. It is a tertiary alpha-hydroxy ketone, a glucocorticoid, a 17alpha-hydroxy steroid, an 11beta-hydroxy steroid, a 20-oxo steroid, a fluorinated steroid, a 3-oxo-Delta(1),Delta(4)-steroid and a chlorinated steroid.

Names & identifiers

Preferred name
Clobetasol
IUPAC
(8S,9R,10S,11S,13S,14S,16S,17R)-17-(2-chloroacetyl)-9-fluoro-11,17-dihydroxy-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one
English name
Clobetasol
Molecular formula
C22H28ClFO4
Molecular weight
410.91

Names & synonyms

clobetasol25122-41-2ClobetasolumDTXSID2048955Clobecort Amex21-Chloro-9-fluoro-11beta,17-dihydroxy-16beta-methylpregna-1,4-diene-3,20-dioneADN79D536H(11beta,16beta)-21-chloro-9-fluoro-11,17-dihydroxy-16-methylpregna-1,4-diene-3,20-dioneDTXCID9028881CHEBI:205919Pregna-1,4-diene-3,20-dione, 21-chloro-9-fluoro-11,17-dihydroxy-16-methyl-, (11beta,16beta)-clobetasolo
Show more names
CLOBETASOLE PROPIONATECLOBETASOL-17-PROPIONATEBetamethasone Impurity BClobetasolBaseClobetasol USP/EP/BPClobetasol Impurity GCLOBESTASOL PROPIONATEBETAMETHASONE EP MPURITY BClobetasol impurity G (PhEur)
Clofenazon(1R,2S,10S,11S,13S,14R,15S,17S)-14-(2-chloroacetyl)-1-fluoro-14,17-dihydroxy-2,13,15-trimethyltetracyclo(8.7.0.0^(2,7).0^(11,15))heptadeca-3,6-dien-5-one(1R,2S,10S,11S,13S,14R,15S,17S)-14-(2-chloroacetyl)-1-fluoro-14,17-dihydroxy-2,13,15-trimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadeca-3,6-dien-5-oneRefChem:54853D07AD01246-633-8(8S,9R,10S,11S,13S,14S,16S,17R)-17-(2-chloroacetyl)-9-fluoro-11,17-dihydroxy-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-oneC22H28ClFO4

Properties

Computed structural propertiesFilling in

XLogP
2.5
Topological polar surface area
74.6 Ų
Hydrogen bond donors
2
Hydrogen bond acceptors
5
Rotatable bonds
2
Heavy atoms
28
Formal charge
0
Complexity
808

Experimental & physicochemical properties

DrugsPharmaceuticals -> Dermatologicals -> Corticosteroids, dermatological preparations
LogP · 3 items

log Kow = 2.48

3

2.48

Solubility1.42e-02 g/L
Human DrugsBreast Feeding; Lactation; Corticosteroids, Topical; Glucocorticoids; Anti-Inflammatory Agents
Endocrine DisruptorsPotential endocrine disrupting compound
Melting Point195.5 - 197 °C
Physical DescriptionSolid
Collision Cross Section201.29 Ų [M+H]+ [CCS Type: TW]
Other Experimental Properties · 2 items

White to cream-colored crystalline powder /Clobetasol propionate/

White or or almost white colorless, crystalline powder, mp: 195.5-197 °C. Specific optical rotation: +103.8 deg at 25 °C/D (c = 1.04 in dioxane). UV max (ethanol): 237 nm (epsilon = 15000). Insoluble in water. /Clobetasol 17-propionate/

Safety & regulation

Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.

GHS classification

GHS Classification · 4 items

Danger

H360 (94.8%): May damage fertility or the unborn child [Danger Reproductive toxicity]

P203, P260, P273, P280, P318, P319, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 58 reports by companies from 5 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

Hazard information

FDA Requirements · 1 item

The Approved Drug Products with Therapeutic Equivalence Evaluations identifies currently marketed prescription drug products, including clobetasol propionate, approved on the basis of safety and effectiveness by FDA under sections 505 of the Federal Food, Drug, and Cosmetic Act. /Clobetasol propionate/

Hazard Classes and CategoriesRepr. 1B (94.8%)

Safety & protection

Storage Conditions · 1 item

Clobetasol propionate cream or ointment should be stored at 15-30 °C; the cream should not be refrigerated. Clobetasol propionate gel should be stored at 2-30 °C. Clobetasol propionate solution should be stored at 4-25 °C; the solution should not be used near an open flame. Clobetasol propionate lotion or shampoo should be stored at 20-25 °C; clobetasol propionate lotion should be protected from freezing. Clobetasol propionate foam should be stored at a controlled room temperature between 20-25 °C, and exposure to temperatures warmer than 49 °C should be avoided.

Disposal Methods · 2 items

SRP: Expired or waste pharmaceuticals shall carefully take into consideration applicable DEA, EPA, and FDA regulations. It is not appropriate to dispose by flushing the pharmaceutical down the toilet or discarding to trash. If possible return the pharmaceutical to the manufacturer for proper disposal being careful to properly label and securely package the material. Alternatively, the waste pharmaceutical shall be labeled, securely packaged and transported by a state licensed medical waste contractor to dispose by burial in a licensed hazardous or toxic waste landfill or incinerator.

Chemistry & industry

Pharmacology

ATC Code · 5 items

D07AD01

D - Dermatologicals

S - Sensory organs

QD - Dermatologicals

QS - Sensory organs

Mechanism of Action · 1 item

Like other topical corticosteroids, clobetasol propionate has anti-inflammatory, antipruritic, and vasoconstrictive properties. The mechanism of the anti-inflammatory activity of the topical steroids, in general, is unclear. However, corticosteroids are thought to act by the induction of phospholipase A2 inhibitory proteins, collectively called lipocortins. It is postulated that these proteins control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes by inhibiting the release of their common precursor, arachidonic acid. Arachidonic acid is released from membrane phospholipids by phospholipase A2.

FDA Pharmacological Classification · 5 items

ADN79D536H

CLOBETASOL

Established Pharmacologic Class [EPC] - Corticosteroid

Mechanisms of Action [MoA] - Corticosteroid Hormone Receptor Agonists

Clobetasol is a Corticosteroid. The mechanism of action of clobetasol is as a Corticosteroid Hormone Receptor Agonist.

MeSH Pharmacological Classification · 2 items

Substances that reduce or suppress INFLAMMATION.

A group of CORTICOSTEROIDS that affect carbohydrate metabolism (GLUCONEOGENESIS, liver glycogen deposition, elevation of BLOOD SUGAR), inhibit ADRENOCORTICOTROPIC HORMONE secretion, and possess pronounced anti-inflammatory activity. They also play a role in fat and protein metabolism, maintenance of arterial blood pressure, alteration of the connective tissue response to injury, reduction in the number of circulating lymphocytes, and functioning of the central nervous system.

Absorption, Distribution and Excretion · 2 items

Following topical application of clobetasol propionate to most areas of normal skin, only small amounts of the drug appear to reach the dermis and subsequently the systemic circulation with the usual dosage; however, systemic absorption may be increased when the usual dosage is exceeded or when the skin is inflamed or diseased. Mean peak plasma clobetasol propionate concentrations of 0.63 ng/mL occurred in one study 8 hours after a second 30-g dose (applied 13 hours after an initial dose) of clobetasol propionate 0.05% ointment in healthy individuals with normal skin; mean peak plasma concentrations of the drug were slightly higher and occurred 10 hours after the second dose when the 0.05% cream was employed. Mean peak plasma concentrations of approximately 2.3 or 4.6 ng/mL occurred in another study about 3 hours after a single application of a 25-g dose of a 0.05% ointment in patients with psoriasis or eczema, respectively.

Related reactions

0 records
New reaction record
No related reactions yet

Compound notes

On this pageBasic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes

Database identifiers

CAS
25122-41-2、25122-46-7
PubChem CID
5311051
DTXSID
DTXSID2048955
ChEMBL
CHEMBL1201362
ChEBI
CHEBI:205919
UNII
ADN79D536H
EC Number
246-633-8
Nikkaji
J19.393C

Physicochemical properties

Melting point
220 · 220-222°C
Boiling point
555.1 · 555.1±50.0 °C(Predicted)
Density
1.32 · 1.32±0.1 g/cm3(Predicted)
storage temp.
-20 °C · -20°C Freezer
solubility
Acetone (Slightly), DMSO (Slightly), Methanol (Slightly)
form
Solid
pka
12.03 · 12.03±0.70(Predicted)
color
White to Light Brown
Henry's Law Constant
6.2 · 6.2×104 mol/(m3Pa) at 25℃, HSDB (2015)
InChIKey
FCSHDIVRCWTZOX-IVGDLNKNNA-N
SMILES
F[C@]12[C@H](C[C@@]3([C@@](O)(C(=O)CCl)[C@@H](C)C[C@@]3([H])[C@]1([H])CCC1=CC(=O)C=C[C@]21C)C)O |&1:1,2,4,5,11,14,16,26,r|
FDA UNII
79 D536H · ADN79D536H
ATC code
7 AD01 · D07AD01
Symbol(GHS)
8 · GHS08
Signal word
Danger
Hazard statements
360 Df-H373-H413 · H360Df-H373-H413
Precautionary statements
201 · P201-P308+P313
Hazard Codes
T
Risk Statements
61 · 61-48/20/21-53-62
Safety Statements
53 · 53-36/37-45
Hazardous Substances Data
25122 · 25122-41-2(Hazardous Substances Data)

SRP: At the time of review, regulatory criteria for small quantity disposal are subject to significant revision, however, household quantities of waste pharmaceuticals may be managed as follows: Mix with wet cat litter or coffee grounds, double bag in plastic, discard in trash.

Toxicology

Environmental Fate · 3 items

TERRESTRIAL FATE: Based on a classification scheme(1), an estimated Koc value of 290(SRC), determined from a log Kow of 2.48(2) and a regression-derived equation(3), indicates that clobetasol is expected to have moderate mobility in soil(SRC). Volatilization of clobetasol from moist soil surfaces is not expected to be an important fate process(SRC) given an estimated Henry's Law constant of 1.6X10-10 atm-cu m/mole(SRC), using a fragment constant estimation method(4). Clobetasol is not expected to volatilize from dry soil surfaces(SRC) based upon an estimated vapor pressure of 1.2X10-12 mm Hg at 25 °C(SRC), determined from a fragment constant method(5). Biodegradation data in soil were not available(SRC, 2011).

AQUATIC FATE: Based on a classification scheme(1), an estimated Koc value of 290(SRC), determined from a log Kow of 2.48(2) and a regression-derived equation(3), indicates that clobetasol is expected to adsorb to suspended solids and sediment(SRC). Volatilization from water surfaces is not expected(4) based upon an estimated Henry's Law constant of 1.6X10-10 atm-cu m/mole(SRC), developed using a fragment constant estimation method(5). According to a classification scheme(6), an estimated BCF of 20(SRC), from its log Kow(2) and a regression-derived equation(3), suggests the potential for bioconcentration in aquatic organisms is low(SRC). Biodegradation data in water were not available(SRC, 2011).

ATMOSPHERIC FATE: According to a model of gas/particle partitioning of semivolatile organic compounds in the atmosphere(1), clobetasol, which has an estimated vapor pressure of 1.2X10-12 mm Hg at 25 °C(SRC), determined from a fragment constant method(2), is expected to exist solely in the particulate phase in the ambient atmosphere. Particulate-phase clobetasol may be removed from the air by wet or dry deposition(SRC). Clobetasol does not contain chromophores that absorb at wavelengths >290 nm(4), and therefore is not expected to be susceptible to direct photolysis by sunlight(SRC).

Soil Adsorption/Mobility · 1 item

The Koc of clobetasol is estimated as 290(SRC), using a log Kow of 2.48(1) and a regression-derived equation(2). According to a classification scheme(3), this estimated Koc value suggests that clobetasol is expected to have moderate mobility in soil.

Human Toxicity Excerpts · 4 items

/HUMAN EXPOSURE STUDIES/ The relatively rapid cutaneous restitution following cutaneous atrophy induced on the forearms of 4 volunteers (aged 20-34 yr) by continuous occlusive application of clobetasol propionate for 6 wk is described.

/CASE REPORTS/ The development of systemic side effects in a 55-yr-old woman with psoriasis after weekly topical application of 25 g clobetasol propionate (Dermovate; I), 0.05% diluted 1 in 4 in white soft paraffin and covering the treated area overnight with cling film, is reported. The patient had cushingoid facies, long, broad, purple striae spreading out onto the trunk and limbs from the groin and axillas, and atrophic plaques of steroid-suppressed psoriasis covering 15% of the trunk and limbs. Adrenal insufficiency developed when the dilution of I was increased to 1 in 16. It was concluded that transepidermal absorption of steroids will increase significantly if the skin is occluded with an impermeable film.

/CASE REPORTS/ A 60-yr-old woman with submammary intertrigo died after excessive topical application of 200 g clobetasol propionate 0.05% and 500 g of 1:4 dilution of the same preparation each week. Necropsy showed extensive venous thrombosis, particularly affecting the inferior vena cava. The kidneys showed tubular necrosis, secondary to the venous obstruction. Autopsy supported the diagnosis of iatrogenic Cushing's syndrome with consequent immobilization resulting in a fatal thrombosis.

/CASE REPORTS/ Four patients who used clobetasol propionate cream over a prolonged period; 3 patients used less than 50 g per week (7.5, 25 and 30 g per week) and yet all developed secondary adrenal failure for up to 4 months after cessation of therapy. Adrenal insufficiency following prolonged use of clobetasol propionate in moderate dosages may therefore be more common than previously recognized. It is suggested that the metyrapone test, which conveniently examines the entire HPA axis, should be employed in patients receiving long-term topical clobetasol propionate cream and that glucocorticoid supplementation should be given during episodes of stress, such as infections and surgery, for up to 4 months after cessation of therapy.

Artificial Pollution SourcesClobetasol's production and use as an anti-inflammatory(1) may result in its release to the environment through various waste streams(SRC).
Drug Induced Liver Injury · 4 items

Drug-Induced Liver Injury Severity and Toxicity (DILIst)

Clobetasol

DILI Positive

DOI:10.1016/j.drudis.2019.09.022

Environmental Bioconcentration · 1 item

An estimated BCF of 20 was calculated in fish for clobetasol(SRC), using a log Kow of 2.48(1) and a regression-derived equation(2). According to a classification scheme(3), this BCF suggests the potential for bioconcentration in aquatic organisms is low(SRC).

Volatilization from Water/Soil · 1 item

The Henry's Law constant for clobetasol is estimated as 1.6X10-10 atm-cu m/mole(SRC) using a fragment constant estimation method(1). This Henry's Law constant indicates that clobetasol is expected to be essentially nonvolatile from water and moist soil surfaces(2). Clobetasol is not expected to volatilize from dry soil surfaces(SRC) based upon an estimated vapor pressure of 1.2X10-12 mm Hg(SRC), determined from a fragment constant method(3).

Non-Human Toxicity Excerpts · 4 items

/LABORATORY ANIMALS: Developmental or Reproductive Toxicity/ In rabbits, clobetasol propionate was teratogenic at doses of 3 and 10 ug/kg. These doses are approximately 0.001 and 0.003 times, respectively, the human topical dose of clobetasol propionate gel, cream and ointment. Abnormalities seen included cleft palate, cranioschisis, and other skeletal abnormalities. In rabbits, clobetasol propionate given by the same route was teratogenic at doses of 3 and 10 mcg/kg. These doses are approximately 0.001 and 0.003 times, respectively, the human topical dose of clobetasol propionate gel. Abnormalities seen included cleft palate, cranioschisis, and other skeletal abnormalities.

/LABORATORY ANIMALS: Developmental or Reproductive Toxicity/ Clobetasol propionate has greater teratogenic potential than steroids that are less potent. Teratogenicity studies in mice using the subcutaneous route resulted in fetotoxicity at the highest dose tested (1 mg/kg) and teratogenicity at all dose levels tested down to 0.03 mg/kg. These doses are approximately 0.33 and 0.01 times, respectively, the human topical dose of clobetasol propionate gel, cream and ointment. Abnormalities seen included cleft palate and skeletal abnormalities.

/LABORATORY ANIMALS: Developmental or Reproductive Toxicity/ Studies in the rat following oral administration /of clobetasol propionate/ at dosage levels up to 50 mg/kg per day revealed that the females exhibited an increase in the number of resorbed embryos and a decrease in the number of living fetuses at the highest dose.

/GENOTOXICITY/ Clobetasol propionate was non-mutagenic in three different test systems: the Ames test, the Saccharomyces cerevisiae gene conversion assay, and the Escherichia coli B WP2 fluctuation test

Environmental Abiotic Degradation · 1 item

The rate constant for the vapor-phase reaction of clobetasol with photochemically-produced hydroxyl radicals has been estimated as 6.7X10-11 cu cm/molecule-sec at 25 °C(SRC) using a structure estimation method(1). This corresponds to an atmospheric half-life of about one hour at an atmospheric concentration of 5X10+5 hydroxyl radicals per cu cm(1). The rate constant for the vapor-phase reaction of clobetasol with ozone has been estimated as 1.3X10-17 cu cm/molecule-sec at 25 °C(SRC) that was derived using a structure estimation method(1). This corresponds to an atmospheric half-life of about 21 hours at an atmospheric concentration of 7X10+11 ozone molecules per cu cm(2). Clobetasol is not expected to undergo hydrolysis in the environment due to the lack of functional groups that hydrolyze under environmental conditions(3). Clobetasol does not contain chromophores that absorb at wavelengths >290 nm(3), and therefore is not expected to be susceptible to direct photolysis by sunlight(SRC).

Probable Routes of Human Exposure · 1 item

Occupational exposure to clobetasol may occur through inhalation and dermal contact with this compound at workplaces where clobetasol is produced or used. Use data indicate that limited general population exposure will occur via ingestion of pharmaceutical products containing clobetasol. (SRC)

Environmental Water Concentrations · 1 item

While data specific to clobetasol were not located(SRC, 2011), the literature suggests that some pharmaceutically active compounds originating from human and veterinary therapy are not eliminated completely in municipal sewage treatment plants and are therefore discharged into receiving waters(1). Wastewater treatment processes often were not designed to remove them from the effluent(2). Selected organic waste compounds may be degrading to new and more persistent compounds that may be released instead of or in addition to the parent compound(2).

Environmental Fate/Exposure Summary · 1 item

Clobetasol's production and use as an anti-inflammatory may result in its release to the environment through various waste streams. If released to air, an estimated vapor pressure of 1.2X10-12 mm Hg at 25 °C indicates clobetasol will exist solely in the particulate phase in the atmosphere. Particulate-phase clobetasol will be removed from the atmosphere by wet or dry deposition. Clobetasol does not contain chromophores that absorb at wavelengths >290 nm, and therefore is not expected to be susceptible to direct photolysis by sunlight. If released to soil, clobetasol is expected to have moderate mobility based upon an estimated Koc of 290. Volatilization from moist soil surfaces is not expected to be an important fate process based upon an estimated Henry's Law constant of 1.6X10-10 atm-cu m/mole. Clobetasol may not volatilize from dry soil surfaces based upon its vapor pressure. If released into water, clobetasol is expected to adsorb to suspended solids and sediment based upon the estimated Koc. Volatilization from water surfaces is not expected to be an important fate process based upon this compound's estimated Henry's Law constant. An estimated BCF of 20 suggests the potential for bioconcentration in aquatic organisms is low. Hydrolysis is not expected to be an important environmental fate process since this compound lacks functional groups that hydrolyze under environmental conditions (pH 5 to 9). Occupational exposure to clobetasol may occur through inhalation and dermal contact with this compound at workplaces where clobetasol is produced or used. Use data indicate that limited general population exposure will occur via ingestion of pharmaceutical products containing clobetasol. (SRC)

Regulatory information

FDA Requirements · 1 item

The Approved Drug Products with Therapeutic Equivalence Evaluations identifies currently marketed prescription drug products, including clobetasol propionate, approved on the basis of safety and effectiveness by FDA under sections 505 of the Federal Food, Drug, and Cosmetic Act. /Clobetasol propionate/

Safety data

risk_code
61-48/20/21-53-62
Signal word
Danger
Symbol(GHS)
GHS08
hazard_code
T
safety_code
53-36/37-45
Hazard statements
H360Df-H373-H413
Precautionary statements
P201-P308+P313
Hazardous Substances Data
25122-41-2(Hazardous Substances Data)

Percutaneous penetration of clobetasol propionate varies among individuals and can be altered by using different vehicles; results of in vitro studies using human skin indicate that absorption of topically applied clobetasol propionate gel is greater than that of topically applied clobetasol propionate cream. Percutaneous penetration can be increased by the use of occlusive dressings and by inflammation and/or other diseases of the epidermal barrier (e.g., psoriasis, eczema).

Cellular LocationsCytoplasm

Uses & manufacturing

Uses · 2 items

MEDICATION

Use (kg; approx.) in Germany (2009): >10

Methods of ManufacturingPreparation: Elks et al., DE 1902340; eidem, US 3721687 (1969, 1973 both to Glaxo)
Formulations/PreparationsTable: Clobetasol Propionate Preparations [Table#7933]

Applications

UsesClobetasol (Clobetasol Propionate EP Impurity G) is a topical corticosteroid. Glucocorticoid; anti-inflammatory.

UsesAtorvastatin Intermediate

Upstream & downstream products

Upstream raw materials

Lithium chloridePropionic anhydride
Additional notes · 1 item

DefinitionChEBI: A 3-oxo-Delta1,Delta4-steroid that is 16beta-methylpregna-1,4-diene-3,20-dione bearing hydroxy groups at the 11beta and 17alpha posit ons, fluorine at position 9, and a chlorine substituent at position 21. It is used as its 17alpha-propionate ester to treat various skin disorders, including exzema and psoriasis.